Compare AbbVie Inc (ABBV) vs Manhattan Associates Inc (MANH) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

MANH trades at $153.81, up 1.83% today, with a bullish technical outlook supported by moving averages and strong support at $150. The company demonstrates robust profitability with a 19.68% net margin and has beaten earnings estimates for three consecutive quarters. However, valuation ratios appear elevated with a P/E of 43.1, while ongoing legal investigations pose sentiment risks.

The stock offers upside to the $192.80 consensus price target but faces headwinds from high valuation multiples and legal uncertainties. Earnings growth and cloud strategy execution remain key catalysts, though investors must weigh these against potential dilution from the fiduciary duty investigations highlighted repeatedly in recent news.